Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.

about

Polymyxin Resistance in Gram-negative Pathogens.Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.

P2860

Q40051834-FD8078D1-3F19-4CF6-B952-F218F2FD4B2C Q47781226-ABBAA43A-6899-49E0-8124-C41FCF0114B5 Q53682528-A1E26FAA-FC6D-476C-871A-7032A1821D7E

P2860

Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.

Item

http://www.wikidata.org/entity/Q41695302

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Nephrotoxicity in Patients wit ...... ymyxin B Compared to Colistin.

@en

type

Item

label

Nephrotoxicity in Patients wit ...... ymyxin B Compared to Colistin.

@en

prefLabel

Nephrotoxicity in Patients wit ...... ymyxin B Compared to Colistin.

@en

P1476

Nephrotoxicity in Patients wit ...... lymyxin B Compared to Colistin

@en

P2093

Craig A Martin

http://www.w3.org/2001/XMLSchema#string

David S Burgess

http://www.w3.org/2001/XMLSchema#string

Donna R Burgess

http://www.w3.org/2001/XMLSchema#string

W Cliff Rutter

http://www.w3.org/2001/XMLSchema#string

P2860

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Estimating creatinine clearance: a meta-analysis.

Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients

Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing

Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity

Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics

High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.

Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill

P31

scholarly article

P356

10.1128/AAC.02329-16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ryan L Crass

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28167560

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

5365730

http://www.w3.org/2001/XMLSchema#string

Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.

about

P2860

P2860

Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932